ALTIUM CAPITAL MANAGEMENT LP
Q2 2024 Form 13-F
NEW YORK, NEW YORK
CIK 0001746382
· Institutional investment manager
$245.1M Reported Value Total
Reported value
$245.1M
Quarter over quarter
-5.4%
Holdings
64
Top-10 concentration
55.9%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Mark Gottlieb
Chief Operating Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 15, 2024 |
| Form | 13F-HR |
| Reported value | $245.1M |
| Positions | 64 |
| Change in reported value | -3.0% |
| New positions | 18 |
| Exited positions | 22 |
| Position turnover | 46.5% |
| Top-10 concentration | 55.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 4, 2026
|
20 | $68.8M |
|
Q2 2026 13F
Filed Aug 12, 2026
|
19 | $47.5M |
|
Q1 2026 13F
Filed May 1, 2026
|
19 | $42.0M |
|
Q4 2025 13F
Filed Feb 6, 2026
|
18 | $25.3M |
|
Q3 2025 13F
Filed Nov 4, 2025
|
1 | $628.3K |
|
Q2 2025 13F
Filed Aug 7, 2025
|
0 | $0 |
|
Q1 2025 13F
Filed May 9, 2025
|
22 | $41.5M |
|
Q4 2024 13F
Filed Feb 13, 2025
|
61 | $352.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
75 | $339.7M |
|
Q2 2024 13F
Filed Aug 15, 2024
|
64 | $245.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
67 | $252.7M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
62 | $147.3M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
65 | $191.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
63 | $132.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
88 | $180.1M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
91 | $196.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
130 | $272.8M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
120 | $249.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
117 | $298.8M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
131 | $362.7M |
4 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | VERA VERA THERAPEUTICS INC | $25.8M | 10.54% |
| 2 | ADMA ADMA BIOLOGICS INC | $16.9M | 6.89% |
| 3 | XENE XENON PHARMACEUTICALS INC | $14.1M | 5.74% |
| 4 | ITCI INTRA-CELLULAR THERAPIES INC | $13.2M | 5.39% |
| 5 | SRPT SAREPTA THERAPEUTICS INC | $12.9M | 5.28% |
| 6 | INSM INSMED INC | $12.7M | 5.19% |
| 7 | ALIM ALIMERA SCIENCES INC | $12.0M | 4.88% |
| 8 | SKYE SKYE BIOSCIENCE INC | $10.8M | 4.41% |
| 9 | ARGX ARGENX SE | $9.9M | 4.04% |
| 10 | SLNO SOLENO THERAPEUTICS INC | $8.7M | 3.54% |
| 11 | AVDL AVADEL PHARMACEUTICALS PLC | $8.6M | 3.5% |
| 12 | CPRX CATALYST PHARMACEUTICALS INC | $7.7M | 3.16% |
| 13 | CTNM CONTINEUM THERAPEUTICS INC | $7.6M | 3.08% |
| 14 | RZLT REZOLUTE INC | $7.3M | 2.98% |
| 15 | ASND ASCENDIS PHARMA A/S | $6.8M | 2.78% |
| 16 | VKTX VIKING THERAPEUTICS INC | $6.5M | 2.64% |
| 17 | SVRA SAVARA INC | $6.3M | 2.59% |
| 18 | ZVRA ZEVRA THERAPEUTICS INC | $5.7M | 2.32% |
| 19 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $5.1M | 2.06% |
| 20 | LRMR LARIMAR THERAPEUTICS INC | $5.0M | 2.05% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.